Product image of Motilium (Domperidone) supplied by GNH India

Motilium

Active Ingredient:
Domperidone
Origin:
EU

Motilium (Domperidone)

Domperidone, the active ingredient in Motilium, is a dopamine D2 receptor antagonist presented as an oral tablet for systemic use. It is employed to relieve nausea and vomiting, improve gastric emptying in gastroparesis, and alleviate symptoms of functional dyspepsia in adult patients.

GNH India supplies Motilium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Manufacturer / TM Owner

Esteve Pharmaceuticals, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Domperidone acts on peripheral dopamine pathways to manage several gastrointestinal and emetic conditions.
  • Nausea and vomiting: reduces episodes by blocking peripheral dopamine receptors in the chemoreceptor trigger zone.
  • Gastroparesis: enhances gastric motility to improve stomach emptying.
  • Functional dyspepsia: relieves upper abdominal discomfort by promoting gastrointestinal transit.

How It Works

  • Domperidone selectively antagonises peripheral dopamine D2 receptors, primarily in the gastrointestinal tract and the chemoreceptor trigger zone. By inhibiting dopamine‑mediated inhibition of gastrointestinal smooth‑muscle activity, it increases gastric motility and accelerates gastric emptying. The same receptor blockade in the vomiting centre reduces the stimulus for nausea and vomiting without crossing the blood‑brain barrier significantly.

Side Effects

Domperidone is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Dry mouth: reduced salivary secretion.
  • Abdominal cramps: mild gastrointestinal discomfort.
  • Headache: transient cephalic pain.
  • Dizziness: sensation of light‑headedness.
  • Diarrhoea or constipation: altered bowel habits.
  • Fatigue: feeling of reduced energy.

Serious or Rare Side Effects

  • Cardiac arrhythmia or QT prolongation: may lead to serious rhythm disturbances.
  • Extrapyramidal symptoms: rare movement disorders.
  • Hyperprolactinemia or galactorrhoea: hormonal effects causing breast discharge.
  • Severe allergic reactions: rash, itching, swelling, or anaphylaxis.
  • Hepatotoxicity: liver enzyme elevation.
  • Neuroleptic malignant‑like syndrome: extremely rare but life‑threatening condition.

Precautions & Warnings

  • Before prescribing domperidone, clinicians should consider several safety aspects.
  • Assess cardiac risk: evaluate QT interval in patients with known cardiac disease.
  • Avoid in prolactin‑dependent tumors: contraindicated in patients with pituitary adenomas.
  • Use caution in hepatic impairment: dose may need adjustment in liver dysfunction.
  • Monitor electrolytes: especially potassium and magnesium levels to reduce arrhythmia risk.
  • Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Avoid Interactions

Domperidone may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase domperidone plasma levels.
  • QT‑prolonging drugs (e.g., quinidine, sotalol): additive risk of arrhythmia.
  • Antifungal agents (e.g., itraconazole): raise systemic exposure.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect.
  • Anticholinergic agents: may enhance anticholinergic side effects.
  • Macrolide antibiotics (e.g., clarithromycin): moderate increase in domperidone concentrations.

Frequently Asked Questions

Motilium, whose active ingredient is domperidone, is prescribed to manage nausea and vomiting, to treat gastroparesis by improving stomach emptying, and to relieve symptoms of functional dyspepsia through its gastro‑prokinetic action.

Domperidone blocks peripheral dopamine D2 receptors located in the gastrointestinal tract and the chemoreceptor trigger zone. This antagonism lifts dopamine‑mediated inhibition of gut motility, enhancing gastric emptying, and reduces the neural signals that trigger nausea and vomiting.

The appropriate dose of Motilium is determined by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and other individual factors. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for domperidone in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Motilium product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with centrally acting anti‑emetics such as metoclopramide, domperidone has limited penetration of the blood‑brain barrier, resulting in fewer central nervous system side effects. However, it shares similar dopamine‑antagonist activity and may require similar cardiac monitoring when combined with QT‑prolonging agents.

Motilium should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Motilium is taken orally, usually with a glass of water. It can be administered with or without food, but patients should follow the specific instructions given by their prescriber regarding timing relative to meals.

The most serious risks include cardiac arrhythmias such as QT prolongation, especially when combined with other QT‑prolonging drugs, and rare endocrine effects like hyperprolactinemia or galactorrhoea. Patients should be monitored for any cardiac symptoms or hormonal changes during therapy.

Motilium is contraindicated in patients with known cardiac arrhythmias, prolonged QT interval, severe hepatic impairment, or a history of prolactin‑dependent tumors. It should also be avoided in individuals taking strong CYP3A4 inhibitors unless the benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Domperidone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT